ERBB2 and neoplasm: The conjugate links to panitumumab, which exhibits affinity to epidermal growth factor receptor (EGFR)-positive tumor cells, or to trastuzumab, which binds specifically to human epidermal growth factor receptor 2 (HER2) receptors [29,30].